Dustin Manders, MD
Gynecologic Oncology · Dallas, TXNPI 1326241324
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $156,959 of the $171,323 with a category attached, or 91.6%. GSK accounts for 79.8% of it on its own, with 36 other manufacturers making up the rest. Among gynecologic oncology clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 216 payments — averaging $793.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$137K
- AstraZeneca$16K
- Eisai Inc.$15K
- Myriad Genetic Laboratories, Inc.$765
- Clovis Oncology, Inc.$372
- Dilon Technologies, Inc.$314
- plus $2K from 31 others
What the payments were for
- Consulting fees$3,0852%
- Speaking & faculty fees$156,95992%
- Travel & lodging$3,0772%
- Food & beverage$8,0995%
- Education$1040%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 73 | $136,790 |
| AstraZeneca | 30 | $15,576 |
| Eisai Inc. | 21 | $15,400 |
| Myriad Genetic Laboratories, Inc. | 14 | $765 |
| Clovis Oncology, Inc. | 6 | $372 |
| Dilon Technologies, Inc. | 2 | $314 |
| Johnson & Johnson(2 entities) | 10 | $311 |
| Merck | 14 | $294 |
| Genmab U.S., Inc. | 2 | $248 |
| Biom'up France SAS | 1 | $140 |
| Novartis | 5 | $125 |
| Hologic Sales And Service, LLC | 1 | $107 |
| Bayer | 4 | $107 |
| Genentech USA, Inc. | 1 | $102 |
| Stemline Therapeutics Inc. | 3 | $69 |
| AbbVie | 3 | $53 |
| Tesaro, Inc. | 2 | $49 |
| Taiho Oncology, Inc. | 2 | $43 |
| Sobi, Inc | 2 | $43 |
| Pfizer | 2 | $40 |
| Lilly USA, LLC | 2 | $37 |
| Deciphera Pharmaceuticals Inc. | 1 | $27 |
| Daiichi Sankyo Inc. | 1 | $26 |
| Jazz Pharmaceuticals Inc. | 1 | $25 |
| Incyte Corporation | 1 | $25 |
| Azurity Pharmaceuticals, Inc. | 1 | $25 |
| Gilead | 1 | $23 |
| Geron Corporation | 1 | $23 |
| Seagen Inc. | 1 | $23 |
| Menarini Silicon Biosystems, Inc. | 1 | $21 |
| EMD Serono, Inc. | 1 | $19 |
| Cumberland Pharmaceuticals, Inc. | 1 | $18 |
| Sanofi | 1 | $18 |
| Amgen | 1 | $18 |
| Astellas Pharma US Inc | 1 | $17 |
| Aspira Women's Health Inc | 1 | $16 |
| Beigene USA, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$171,323 in reported general payments places this provider in the 95th percentile of 135 gynecologic oncology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RubracaRucaparib Camsylate | 27 | $361,769 |
| LynparzaOlaparib | 23 | $351,207 |
| EliquisApixaban | 23 | $16,015 |
| Gabapentin | 69 | $1,666 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 82 | $1,463 |
| Ondansetron Hcl | 44 | $347 |
| Prochlorperazine Maleate | 33 | $258 |
| Dexamethasone | 17 | $244 |
| Letrozole | 20 | $236 |
| Duloxetine Hcl | 12 | $156 |
| Tramadol Hcl | 12 | $70 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Clovis Oncology, Inc.Rubraca | $372 | $361,76927 claims |
| AstraZenecaLynparza | $15,576 | $351,20723 claims |
| PfizerEliquis | $40 | $16,01523 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 135 gynecologic oncology providers in Texas.
Other gynecologic oncology in Dallas
- David MillerDallas$101K
- Thomas HeffernanDallas$95K
- Jayanthi LeaDallas$12K
- Jonathan OhDallas$7K
- Jessica GillenDallas$6K
- Brandon RoaneDallas$4K
- Bruce FineDallas$4K
- Laura DivineDallas$4K
- Erik KoonDallas$4K
- Alan MunozDallas$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.